Identification of global inhibitors of cellular glycosylation

• Published in: Nature communications Vol. 14; no. 1; p. 948
• Main Authors: Sørensen, Daniel Madriz, Büll, Christian, Madsen, Thomas D., Lira-Navarrete, Erandi, Clausen, Thomas Mandel, Clark, Alex E., Garretson, Aaron F., Karlsson, Richard, Pijnenborg, Johan F. A., Yin, Xin, Miller, Rebecca L., Chanda, Sumit K., Boltje, Thomas J., Schjoldager, Katrine T., Vakhrushev, Sergey Y., Halim, Adnan, Esko, Jeffrey D., Carlin, Aaron F., Hurtado-Guerrero, Ramon, Weigert, Roberto, Clausen, Henrik, Narimatsu, Yoshiki
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 20.02.2023; Nature Publishing Group; Nature Portfolio
• Subjects: 13; 13/1; 13/106; 13/31; 14/19; 14/63; 631/45/612/1231; 631/80/221; 631/80/458/1524; 631/92/96; Animals; Antibodies; Binding; COVID-19; Drug development; Enzyme inhibitors; Glycan; Glycoproteins; Glycoproteins - metabolism; Glycosylation; Golgi cells; Heparan sulfate; Humanities and Social Sciences; Inhibitors; Low density lipoprotein receptors; multidisciplinary; Polysaccharides; Polysaccharides - metabolism; Receptor density; SARS-CoV-2 - metabolism; Science; Science (multidisciplinary); Screening; Secretion; Severe acute respiratory syndrome coronavirus 2
• ISSN: 2041-1723; 2041-1723
• DOI: 10.1038/s41467-023-36598-7

Small molecule inhibitors of glycosylation enzymes are valuable tools for dissecting glycan functions and potential drug candidates. Screening for inhibitors of glycosyltransferases are mainly performed by in vitro enzyme assays with difficulties moving candidates to cells and animals. Here, we circumvent this by employing a cell-based screening assay using glycoengineered cells expressing tailored reporter glycoproteins. We focused on GalNAc-type O-glycosylation and selected the GalNAc-T11 isoenzyme that selectively glycosylates endocytic low-density lipoprotein receptor (LDLR)-related proteins as targets. Our screen of a limited small molecule compound library did not identify selective inhibitors of GalNAc-T11, however, we identify two compounds that broadly inhibited Golgi-localized glycosylation processes. These compounds mediate the reversible fragmentation of the Golgi system without affecting secretion. We demonstrate how these inhibitors can be used to manipulate glycosylation in cells to induce expression of truncated O-glycans and augment binding of cancer-specific Tn-glycoprotein antibodies and to inhibit expression of heparan sulfate and binding and infection of SARS-CoV-2. Here, the authors discover small molecules that inhibit glycosylation processes that occur in the Golgi apparatus of cells. The molecules reversibly inhibit formation of elaborate glycan structures without affecting secretion of glycoproteins.